vimarsana.com

Latest Breaking News On - Oliver dorigo - Page 1 : vimarsana.com

Early Data for CRX100 Pave Way for Potential Combinations in Recurrent, Platinum-Resistant Ovarian Cancer

MVP-S Plus Low-Dose Cyclophosphamide Elicits Robust Responses in Recurrent Ovarian Cancer

Oliver Dorigo, MD, PhD, explains how MVP-S leverages the DPX platform to produce persistent anti-survivin immune infiltration, highlights the antitumor activity and safety observed with the combination when given to patients with recurrent ovarian cancer, and describes additional research efforts underway.

Dr Dorigo on the Clinical Benefit with Maveropepimut-S in Recurrent Ovarian Cancer

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.